

Legend Drug Information for Connecticut Prescribing Practitioners and Pharmacists

KIMYRSA® (oritavancin)

The price listed below is the Wholesaler Acquisition Cost ("WAC") as established and made available to the public by a third-party publisher, PriceRx. The price paid by consumers may be higher or lower than the price listed below. This information is provided to Connecticut prescribing practitioners and pharmacists pursuant to Connecticut law.

Marketed Product:

Drug	Package Size	WAC	Quantity
KIMYRSA® (oritavancin)	1200 mg	\$5,827.87	1

Efficacy within different racial/ethnic groups

Population pharmacokinetic analysis from the Phase 3 ABSSSI trials in patients indicated that race had no clinically relevant effect on the exposure of oritavancin. The clinical response rates for the primary and secondary efficacy outcomes were also similar across racial subgroups in the Phase 3 ABSSSI trials. No dosage adjustment of KIMYRSA is warranted in these subpopulations.

PriceRx is the source of the enclosed WAC information. This document is current as of July 1, 2026.

Signature Page for PP-KIM-US-0278 v6.0

Task: Assess Outcome	Jennifer Block
	02-Jul-2026 04:51:42 GMT+0000

Signature Page for PP-KIM-US-0278 v6.0